COMMUNIQUÉS West-GlobeNewswire

Nyxoah Annonce la Clôture de l’Offre et l’Exercice Partiel de l’Option d’Achat d’Actions Supplémentaires
31/05/2024
INFORMATIONS PRIVILÉGIÉES INFORMATIONS RÉGLEMENTÉES Nyxoah Annonce la Clôture de l’Offre et l’Exercice Partiel de l’Option d’Achat d’Actions Supplémentaires Mont-Saint-Guibert, Belgique – 31 mai 2024, 8h00 CET / 2h00 ET [...]
Nicox annonce l’organisation d’un webcast pour ses actionnaires le 6 juin 2024 à 18h00 CET à l’occasion de son augmentation du capital déjà en cours
31/05/2024
Communiqué de presse Nicox annonce l’organisation d’un webcast pour ses actionnaires le 6 juin 2024 à 18h00 CET à l’occasion de son augmentation du capital déjà en cours 31 mai 2024 – diffusion à 07h30 Sophia Antipolis [...]
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
31/05/2024
Recommendation for adults with uncontrolled COPD with raised blood eosinophils based on data from two landmark Phase 3 trials demonstrating Dupixent significantly reduced exacerbations and improved lung function If [...]
Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD
31/05/2024
Dupixent recommended for EU approval by the CHMP to treat patients with COPD Recommendation for adults with uncontrolled COPD with raised blood eosinophils based on data from two landmark Phase 3 trials demonstrating [...]
Communiqué de presse : Le CHMP recommande l'approbation de Dupixent dans l'UE pour le traitement des patients atteints de BPCO
31/05/2024
Le CHMP recommande l'approbation de Dupixent dans l'UE pour le traitement des patients atteints de BPCO Recommandation pour les adultes atteints d’une BPCO non contrôlée avec éosinophilie sanguine élevée, basée sur les [...]
Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation
31/05/2024
TARRYTOWN, N.Y. and PARIS, May 31, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced the U.S. Food and Drug Administration (FDA) has extended by three months the target [...]
Addex Therapeutics to Release Q1 2024 Financial Results and Host Conference Call on June 6, 2024
31/05/2024
Geneva, Switzerland, May 31, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological [...]
Data from the PRECISION study of aprocitentan to be presented at the European Society of Hypertension Annual Meeting 2024
31/05/2024
Allschwil, Switzerland – May 31, 2024 Idorsia Ltd (SIX: IDIA) today announced that data from the Phase 3 study of aprocitentan, Idorsia’s endothelin receptor antagonist, will be presented by Prof. Krzysztof Narkiewicz, [...]
BioSenic S.A. : Information on the total number of voting rights and shares
31/05/2024
PRESS RELEASE – REGULATED INFORMATION Mont-Saint-Guibert, Belgium, May 31, 2024, 7.00 am CEST – BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and [...]
BioSenic S.A. : Information relative au nombre total de droits de vote et d’actions
31/05/2024
COMMUNIQUE DE PRESSE – INFORMATION REGLEMENTEE Mont-Saint-Guibert, Belgique, le 31 mai 2024 à 07h00 CEST – BIOSENIC (Euronext Bruxelles et Paris: BIOS), la société en phase clinique spécialisée dans les maladies auto- [...]
Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammation
31/05/2024
Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammation Paris and Tarrytown, NY May 31, 2024 . The US Food and Drug Administration (FDA) has extended by three months the [...]
Communiqué de presse : Point d’actualité sur l’examen prioritaire de la FDA relatif au Dupixent pour le traitement de la BPCO avec inflammation de type 2
31/05/2024
Point d’actualité sur l’examen prioritaire de la FDA relatif au Dupixent pour le traitement de la BPCO avec inflammation de type 2 Paris et Tarrytown (New York), le 31 mai 2024 . La Food and Drug Administration (FDA) [...]
CloudMD Reports First Quarter 2024 Results
31/05/2024
First Quarter Highlights Q1 Revenue of $22.8 million compared to $22.6 million in Q4 2023 and $22.9 million in the prior year. Q1 2024 gross profit margin of 37.0% increased from 36.9% in the prior year. Q1 Adjusted [...]
Syncromune, Inc. Announces FDA Clearance of IND Application for SYNC-T SV-102, a First-In-Class Combination Multi-Target Immunotherapy for Metastatic Castrate-Resistant Prostate Cancer
31/05/2024
SYNC-T SV-102 Therapy combines partial tumor oncolysis with a fixed-dose combination multi-target biologic drug to provide a novel, personalized therapeutic approach for the treatment of metastatic castrate-resistant [...]
Telix Announces Positive rPFS Data from ProstACT SELECT Trial of TLX591 rADC Therapy Candidate in Prostate Cancer
31/05/2024
TLX591 is an investigational anti-PSMA 1 radio-antibody-drug conjugate (rADC) therapy being developed for the treatment of mCRPC, differentiated by a short two-week dosing regimen. Reported median radiographic [...]
Hydreight Reports Record Topline(1) Revenue of $4.87M in Q1-2024 (YOY Increase of 33%)
31/05/2024
“We had an outstanding quarter with record revenue...Our focus in 2024 is to continue growing revenue, becoming a profitable company and introducing our story to more potential shareholders” - Shane Madden, CEO of [...]
Jasper Therapeutics to Present Data on Briquilimab in Mast Cell Driven Diseases at the EAACI Congress 2024
31/05/2024
REDWOOD CITY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting [...]
Novartis Phase III data confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria
31/05/2024
Patients treated with remibrutinib experienced improvements in weekly urticaria activity scores (UAS7) observed as early as Week 1 and sustained to 1 year (Week 52) 1 Remibrutinib, an oral Bruton’s tyrosine kinase [...]
Goodness Growth Holdings to Complete Non-Brokered Private Placement to Support the Relocation of a Minnesota Dispensary
31/05/2024
MINNEAPOLIS, May 30, 2024 (GLOBE NEWSWIRE) -- Goodness Growth Holdings, Inc. ("Goodness Growth" or the "Company") (CSE: GDNS; OTCQX: GDNSF), a cannabis company committed to providing safe access, quality products and [...]

Pages